Roughly a year ago, Stanford University professor Brian Kobilka was in the spotlight, participating in a press conference after winning the 2012 Nobel Prize in Chemistry, along with Duke University’s Robert Lefkowitz, for studies of G-protein-coupled receptors (GPCR) – the target of some 50 percent of currently marketed drugs, according to background information on the prize cited by the Royal Swedish Academy.